AU2017229591B2 - Calpain modulators and methods of production and use thereof - Google Patents

Calpain modulators and methods of production and use thereof Download PDF

Info

Publication number
AU2017229591B2
AU2017229591B2 AU2017229591A AU2017229591A AU2017229591B2 AU 2017229591 B2 AU2017229591 B2 AU 2017229591B2 AU 2017229591 A AU2017229591 A AU 2017229591A AU 2017229591 A AU2017229591 A AU 2017229591A AU 2017229591 B2 AU2017229591 B2 AU 2017229591B2
Authority
AU
Australia
Prior art keywords
substituted
heteroaryl
group
aryl
ring structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017229591A
Other languages
English (en)
Other versions
AU2017229591A1 (en
Inventor
Brad Owen BUCKMAN
Shendong Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blade Therapeutics Pty Ltd
Original Assignee
Blade Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blade Therapeutics Pty Ltd filed Critical Blade Therapeutics Pty Ltd
Publication of AU2017229591A1 publication Critical patent/AU2017229591A1/en
Application granted granted Critical
Publication of AU2017229591B2 publication Critical patent/AU2017229591B2/en
Assigned to Blade Therapeutics Pty Ltd reassignment Blade Therapeutics Pty Ltd Request for Assignment Assignors: BLADE THERAPEUTICS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2017229591A 2016-03-09 2017-03-08 Calpain modulators and methods of production and use thereof Ceased AU2017229591B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306040P 2016-03-09 2016-03-09
US62/306,040 2016-03-09
PCT/US2017/021288 WO2017156074A1 (fr) 2016-03-09 2017-03-08 Modulateurs de calpaïne et leurs méthodes de production et d'utilisation

Publications (2)

Publication Number Publication Date
AU2017229591A1 AU2017229591A1 (en) 2018-10-25
AU2017229591B2 true AU2017229591B2 (en) 2021-08-19

Family

ID=59790788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017229591A Ceased AU2017229591B2 (en) 2016-03-09 2017-03-08 Calpain modulators and methods of production and use thereof

Country Status (2)

Country Link
AU (1) AU2017229591B2 (fr)
WO (1) WO2017156074A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CA3038331A1 (fr) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Modulateurs de calpain et leurs utilisations therapeutiques
EP3564211A1 (fr) 2018-05-03 2019-11-06 Landsteiner Genmed, S.L. Derives de dipeptidyl ketoamide meta-methoxyphenyl et leurs utilisations
CN113773228A (zh) * 2021-10-28 2021-12-10 上海吉奉生物科技有限公司 一种n-苄氧羰基-3-碘-l-丙氨酸甲酯的合成方法
EP4234014A1 (fr) * 2022-02-28 2023-08-30 Insusense ApS Carbamates et/ou urées dérivés d'acides amninés pour le traitement de maladies liées à la sortiline
CN115124448A (zh) * 2022-07-20 2022-09-30 杭州国瑞生物科技有限公司 一种一锅法合成d-焦谷氨酸衍生物的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048121A2 (fr) * 2006-10-18 2008-04-24 Lincoln University Composés et compositions
WO2013166319A1 (fr) * 2012-05-02 2013-11-07 Kansas State University Research Foundation Composés macrocycliques et peptidomimétiques en tant qu'antiviraux à large spectre contre des protéases 3c ou de type 3c de picornavirus, calicivirus et coronavirus
WO2015179441A2 (fr) * 2014-05-20 2015-11-26 Rqx Pharmaceuticals, Inc. Antibiotiques macrocycliques à large spectre

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048121A2 (fr) * 2006-10-18 2008-04-24 Lincoln University Composés et compositions
US20110021434A1 (en) * 2006-10-18 2011-01-27 Andrew David Abell Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof
WO2013166319A1 (fr) * 2012-05-02 2013-11-07 Kansas State University Research Foundation Composés macrocycliques et peptidomimétiques en tant qu'antiviraux à large spectre contre des protéases 3c ou de type 3c de picornavirus, calicivirus et coronavirus
US20150133368A1 (en) * 2012-05-02 2015-05-14 Kansa State University Research Foundation Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses
WO2015179441A2 (fr) * 2014-05-20 2015-11-26 Rqx Pharmaceuticals, Inc. Antibiotiques macrocycliques à large spectre

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ABELL, A. D. et al., "Molecular modeling, synthesis, and biological evaluation of macrocyclic calpain inhibitors", Angewandte Chemie , International Edition, (2009), vol. 48, no. 8, pages 1455 - 1458 *
CHEN, H. et al., "New Tripeptide-Based Macrocyclic Calpain Inhibitors Formed by N- Alkylation of Histidine", Chemistry & Biodiversity, (2012), vol. 9, no. 11, pages 2473 - 2484 *
DAMALANKA, V. C. et al., "Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease", Journal of Medicinal Chemistry, (2016), vol. 59, no. 5, pages 1899 - 1913 *
JONES, M. A. et al., "Efficient large-scale synthesis of CAT811, a potent calpain inhibitor of interest in the treatment of cataracts", Australian Journal of Chemistry, (2009), vol. 62, no. 7, pages 671 - 675 *
JONES, S. A. et al., "A Template-Based Approach to Inhibitors of Calpain 2, 20S Proteasome, and HIV-1 Protease", ChemMedChem, (2013), vol. 8, no. 12, pages 1918 - 1921 *
JONES, S. A. et al., "The Preparation of Macrocyclic Calpain Inhibitors by Ring Closing Metathesis and Cross Metathesis", Australian Journal of Chemistry, (2014), vol. 67, no. 8 - 9, pages 1257 - 1263 *
MANDADAPU, S. R. et al., "Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus", Bioorganic & Medicinal Chemistry Letters, (2013), vol. 23, no. 13, pages 3709 - 3712 *
MORTON, J. D. et al., "A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model", Investigative Ophthalmology & Visual Science, (2013), vol. 54, no. 1, pages 389 - 395 *
PEHERE, A D. et al., "New cylindrical peptide assemblies defined by extended parallel beta- sheets", Organic & Biomolecular Chemistry, (2013), vol. 11, no. 3, pages 425 - 429 *
PEHERE, A. D. et al., "New beta-strand templates constrained by Huisgen cycloaddition", Organic Letters, (2012), vol. 14, no. 5, pages 1330 - 1333 *
PEHERE, A.D. et al., "Synthesis and Extended Activity of Triazole-Containing Macrocyclic Protease Inhibitors", Chemistry - A European Journal, (2013), vol. 19, no. 24, pages 7975 - 7981 *
STUART, B. G. et al., "Molecular Modeling: A Search for a Calpain Inhibitor as a New Treatment for Cataractogenesis", Journal of Medicinal Chemistry, (2011), vol. 54, no. 21, pages 7503 - 7522 *
WALKER, M. A. et al., "General method for the synthesis of cyclic peptidomimetic compounds", Tetrahedron Letters, (2001), vol. 42, no. 34, pages 5801 - 5804 *

Also Published As

Publication number Publication date
WO2017156074A1 (fr) 2017-09-14
AU2017229591A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
AU2017229591B2 (en) Calpain modulators and methods of production and use thereof
BR112021022419B1 (pt) Compostos antivirais contendo nitrila e composição farmacêutica
ES2972487T3 (es) Formas sólidas de un inhibidor de tienopirimidindiona acc y métodos para la producción del mismo
US12012467B2 (en) Small molecule DCN1 inhibitors and therapeutic methods using the same
CN107531693B (zh) 作为吲哚胺、色氨酸二加氧酶抑制剂的5或8-取代的咪唑并[1，5-a]吡啶
US10590084B2 (en) Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
CN107531727B (zh) 多环氨甲酰基吡啶酮化合物及其药物用途
EA026114B1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EP3177611B1 (fr) Derives de pyrimidine eventuellement condensee substituee par un heterocycle utiles dans le traitement de maladies inflammatoires, metaboliques, oncologiques et auto-immunes
EA019749B1 (ru) Противовирусные соединения
EA023223B1 (ru) ПИРАЗОЛ[1,5-a]ПИРИМИДИНЫ ДЛЯ ПРОТИВОВИРУСНОГО ЛЕЧЕНИЯ
CN111406063A (zh) 作为抗癌剂的环二核苷酸
EP2900684A2 (fr) Peptides cycliques et utilisations en tant que médicaments
TW201416363A (zh) Ｃ型肝炎病毒抑制劑
WO2019217465A1 (fr) Modulateurs de calpain et leurs utilisations thérapeutiques
CN109796519B (zh) 一类甾体化合物及其应用
US9782392B2 (en) Azaindole derivative
ES2941771T3 (es) Derivados de dihidrocromeno
CN112218878A (zh) Ntcp抑制剂
CA2989989C (fr) Compose pyrrolo[2,3-d]pyrimidine ou un sel de celui-ci
US11708348B2 (en) Protease inhibitors for treatment of coronavirus infections
RU2786722C1 (ru) Нитрилсодержащие противовирусные соединения
WO2015158306A1 (fr) Inhibiteur irréversible de la glyoxalase i, son procédé de préparation et utilisations associées
BR112018001695B1 (pt) COMPOSTO PIRROLO[2,3-d]PIRIMIDINA, INIBIDOR DE JAK3, COMPOSIÇÃO FARMACÊUTICA, AGENTE, USOS DO DITO COMPOSTO E MÉTODO PRA PRODUÇÃO DO MESMO

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BLADE THERAPEUTICS PTY LTD

Free format text: FORMER APPLICANT(S): BLADE THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired